ChangeDetection - Change Log: Cancer Diagnostics and Testing, Molecular Diagnostics ...

Cancer Diagnostics and Testing, Molecular Diagnostics ...

Current status: normal - monitoring
Number of users monitoring this page: 0
Most recent sizable change (text, html) : 2012-01-20 11:10
Most recent change (text, html) : 2012-01-20 11:10
Last checked for changes: 2012-02-13 13:36
ChangeDetection started monitoring: 2008-02-04 10:25

monitor this page

summary of most recent changes

Showing 1 - 5 of 24

1 2 3 4 [next]

show added and deleted only added only deleted | show context hide context | show sizable show all

View changes: 2012-01-20 11:10 46 new words, 21 deleted words, 18% change

... more about Clarient. Reduce your patient’s anxiety with test ... … not weeks. Clarient’s InsightDx Mammostrat, a highly validated breast panel, provides clinicians a risk of recurrence assessment, important information independent of proliferation and grade, at the time of hormonal statusto aid physicians in making appropriate and earlier ... are most likely to recur from breast cancer. Learn more Now ... more about Clarient. Reduce your patient’s anxiety with test ... … not weeks. Clarient’s InsightDx Mammostrat... provides important information independent of proliferation and gradeto aid physicians in making appropriate and earlier ... are most likely to recur from breast cancer. Learn more Now more about Clarient. ... Mammostrat, a highly validated breast panel, provides clinicians a risk of recurrence assessment, independent of proliferation and grade, at the time of hormonal status. Learn more Now more...

View changes: 2011-11-30 11:18 20 new words, 40 deleted words, 16% change

... . Learn More Now available Available BRAF V600 Mutation in Melanoma Confirmation of BRAF V600 mutation-positive melanoma as detected by the The FDA approved ALK Break Apart FISH Probe Kit for metastatic NSCLC. The FDA approved cobas ® 4800 FDA-approved test is required for selection of patients for ZELBORAF therapy because these are ... only patients studied and for whom benefit is knownmetastatic Melanoma... . Learn More Now Available The FDA approved ALK Break Apart FISH Probe Kit for metastatic NSCLC. The FDA approved cobas ® 4800 ... for metastatic Melanoma. Learn More Top . Learn More Now available BRAF V600 Mutation in Melanoma Confirmation of BRAF V600 mutation-positive melanoma as detected by the cobas ... 4800 FDA-approved test is required for selection of patients for ZELBORAF therapy because these are ... only patients studied and for whom benefit is known. Learn More Top more...

View changes: 2011-09-24 10:25 48 new words, 26 deleted words, 20% change

... status. Learn More Clarient's new lung cancer Now available BRAF V ... the cobas 4800 FDA-approved test helps physicians differentiate histologic sub-classes is required for selection of non-small cell lung cancer ... ), leading to better patients for ZELBORAF therapy selection because these are the only patients studied and for patientswhom benefit is known. Learn more about More InsightDx Pulmotype . ... status. Learn More Now available BRAF V ... the cobas 4800 FDA-approved test is required for selection of patients for ZELBORAF therapy because these are the only patients studied and for whom benefit is known. Learn More Top Tests ALK Rearrangement by FISH BRAF BRAF V600 Mutation-Melanoma EGFR Mutation Analysis KRAS status. Learn More Clarient's new lung cancer test helps physicians differentiate histologic sub-classes of non-small cell lung cancer ... ), leading to better therapy selection for patients. Learn more about InsightDx Pulmotype . Top Tests ALK Rearrangement by FISH BRAF ... EGFR Mutation Analysis KRAS more...

View changes: 2011-09-19 10:25 2 new words, 184 deleted words, 36% change

... If you missed the latest webinars, please click on the links below. here Pathologic Management of Non-Small Cell Lung Cancer Hosted by Dr. John Glassco View the Webinar ... CST | 11:00 am EST Contact Us | Trademarks If you missed the latest webinars, please click here . ... Contact Us | Trademarks If you missed the ... webinars, please click on the links below. Pathologic Management of Non-Small Cell Lung Cancer Hosted by Dr. John Glassco View the Webinar ... CST | 11:00 am EST Contact Us | Trademarks more...

View changes: 2011-09-17 10:25 1 new words, 12 deleted words, 2% change

... about InsightDx Pulmotype . If you missed our Pulmotype ... , see our playback. Top Tests ALK Rearrangement ... industry. If you miss missed the webinars, please about InsightDx Pulmotype . ... industry. If you missed the webinars, please about InsightDx Pulmotype . If you missed our Pulmotype ... , see our playback. Top Tests ALK Rearrangement ... industry. If you miss the webinars, please more...

link to this change log

Changes to the page www.clarientinc.com are logged on this page as they are detected. You can link to this log by pasting the HTML below into your page. It produces a link which looks like this: change log

Cancer Diagnostics and Testing, Molecular Diagnostics ...

monitor this page

summary of most recent changes

link to this change log

log in

search